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Saudi gene polymorphismAbstract Glucuronidation is an important phase II pathway responsible for many endogenous
substances and drug metabolism. The present work evaluated allele frequencies of certain UDP-
glucuronosyl-transferases (UGT 1A6*2, A7*12, A8*3, A9*3, 2B7*2, and 2B15*2) in Saudi Arabi-
ans that could provide essential ethnic information. Blood samples from 192 healthy unrelated
Saudi males of various geographic regions were collected. Genomic DNA was isolated and geno-
typing of various UGTs was carried out using polymerase chain reaction (PCR) followed by direct
sequencing. For UGT1A6*2 A/G genotype, the most common variant was the homozygous repeat
(AA) and the most common allele was (A) with a frequency of 46.5% and 67.3%, respectively. Sim-
ilarly, the most common variant for UGT1A7*12 T/C genotype was the heterozygous repeat (TC)
with a frequency of 78.7% while the mutant allele (C) was present in 60.6% of the study population.
Both UGT1A8*3 (G/A) and UGT1A9*3 (T/C) showed only a wild homozygous pattern in all
screened subjects. For UGT2B7*2, the heterozygous repeat (TC) was found with a frequency of
57.3% and the alleles (A) showed a frequency of 50.8%. In contrast, for UGT2B15*2 (G253T),
the heterozygous repeat (TG) presented 62.3% of the subjects where the most common allele (G)
was with a frequency of 66.2%. In conclusion, our data indicate that Saudis harbor some important1, Saudi
7*2, and
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2B15*2) in a Saudi population. Saudi PharmUGT mutations known to affect enzyme activity. Additional studies are therefore, warranted to
assess the clinical implications of these gene polymorphisms in this ethnic group.
 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is
an open access article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Glucuronidation is an essential metabolic process that is the
basis of the detoxification of many drugs and other substances
which are mainly taken as various edible forms. There is signif-
icant evidence that confirms that the drug elimination and
other processes in detoxification display vast inter-individual
differences, resulting in variability in both potency and toxic-
ity. For example, during the past few years, multiple drugs
used against lung cancer (Slatter et al., 1997; Senderowicz,
2000; Shapiro et al., 2001), colorectal cancer (Iyer et al.,
1998; Ando et al., 2000), renal cancer (Innocenti et al.,
2000), HIV (Zucker et al., 2001) and B-cell chronic lympho-
cytic leukemia (Chao and Price, 2001) have led to substantial
toxic reactions owing to inter-patient differences in the pro-
cesses of glucuronidation. This is not surprising, as it has been
found that the families of Uridine diphospho-glucuronosyl-tr
ansferases (UGTs) are highly polymorphic, and according to
the norms of inheritance several monogenic features are pre-
dictors of toxicity. Therefore, determining the allelic frequency
of these important genes will serve in explaining their role in
drug disposition and toxicity.
UGTs are glycoproteins, present in endoplasmatic reticu-
lum (ER) and nuclear membranes that convert many endoge-
nous agents and xenobiotics to less active counterparts that are
more water soluble by the conversion of aglycones to D-
glucopyronosiduronic acids (glucuronides). In particular, the
glucuronidation reactions catalyzed by UGTs are also respon-
sible for clearance of endogenous substrates including thyroid
hormones, steroid hormones, bilirubin and bile acids (Tukey
and Strassburg, 2000). Consequently, changes in UGTs
enzyme function may eventually affect clearance of, and there-
fore, systemic exposure to those compounds.
Different groups of UGT genes have been identified, each
of which includes multiple genes. All of the UGT enzymes pro-
duced from these genes have a similar area that identifies
UDP-glucuronic acid. UGT1A, on the long arm of chromo-
some 2 in humans, consists of at least 9 promoters and first
exons that can be spliced with four common exons to produce
UGT1A1–UGT1A9. The UGT2 family, on the other hand, is
divided into 2A (three genes) and 2B (seven genes) subfamilies
on chromosome 4. Several functional polymorphisms in UGT
1A and 2B subfamilies are associated with altered glucuronida-
tion activity of important endogenous compounds and clini-
cally used drugs (Tukey and Strassburg, 2001).
UGTs are expressed in a tissue specific fashion in humans,
which enables most of the tissues to form glucuronides.
Because of the tissue specific regulation of these proteins, each
tissue contains a distinct pattern of UGT proteins (Tukey and
Strassburg, 2000, 2001). This suggests that the beneficial prop-
erties of UGTs in different tissues may have evolved over a
period of time to meet the unique challenges essential for glu-
curonidation. This is best illustrated by the extra-hepatic
expression of UGT1A7 (Strassburg et al., 1997), UGT1A8.M. et al., Prevalence of UDP-glucurono
aceutical Journal (2016), http://dx.doi.and UGT1A10 (Strassburg et al., 1998a,b), all of which are
present in various tissues of the intestinal tract. Since UGTs
are present in a high concentration in the intestinal tract
(Tukey and Strassburg, 2001; Strassburg et al., 1998b, 1999),
they are thought to play a significant role in the first pass meta-
bolism, and therefore variations in function emerging from
pharmacogenetic differences may determine systemic drug
levels and therapeutic outcome.
Given the clinical importance of certain UGTs polymor-
phisms, the focus of this study was to investigate the frequen-
cies of UGT1A6*2, A7*12, A8*3, A9*3, 2B7*2, and 2B15*2 in
Saudi Arabians and thus therefore providing essential infor-
mation on this specific ethnic group. This should also shed
some light on the clinical implication of these mutations in
relation to disease occurrence and therapeutic efficacy and tox-
icity of drugs known to be metabolized by these variants.
2. Materials and methods
2.1. Human subjects
A total of 192 apparently healthy unrelated Saudi male volun-
teers (20–25 year-old) of various geographic regions were
recruited to the study from King Saud University, Riyadh,
Saudi Arabia. The study’s objectives were explained and one
time venous blood sample (20 ml) was obtained in EDTA
tubes from each subject after obtaining written informed con-
sent from all participants. The ethical approval of the study
was granted by the Institutional Review Board of the College
of Medicine, King Saud University, Riyadh, Saudi Arabia.
2.2. Genetic testing
DNA extraction was carried out using Puregene Blood Core
Kit C (Qiagen, Germantown, MD, USA) following manufac-
turer’s instructions and quantified using Nanodrop 2000 Spec-
trophotometer (Thermo Scientific, Wilmington, DE, USA).
The indicated polymorphic variants were amplified in a Ver-
iti 96-Well Fast Thermal Cycler (Applied Biosystems, Foster
City, CA, USA) in a total volume of 25 ll, containing 20 ng
DNA, 0.25 ll (2.5 mM) of dNTPs (Epicentre Biotechnologies,
Madison, WI, USA), 2 ll (10 pM) of primers (Metabion,
Martinsried, Germany) and 0.3 ll (5 U/ll) of Hotstar Taq
DNA polymerase (Qiagen, Germantown, MD, USA). For
PCR, an initial denaturation step at 95 C for 10 min was fol-
lowed by 35 cycles of denaturation at 94 C for 40 s, annealing
at the indicated temperature for 40 s, and extension at 72 C
for 45 s, followed by a final extension step of 72 C for
10 min. Primers’ sequences are listed in Table 1 with their
respective annealing temperature of 56 C. The PCR ampli-
cons were evaluated by 2% agarose gel electrophoresis and
then purified using MCE-membraned Multi-Screen plate (Mil-
lipore, Billerica, MA, USA) pre-packed with G-50 superfine
cephadex (GE Healthcare, Piscataway, NJ, USA). The purifiedsyltransferase polymorphisms (UGT1A6*2, 1A7*12, 1A8*3, 1A9*3, 2B7*2, and
org/10.1016/j.jsps.2016.05.009
Table 1 UGT allele frequencies with primers’ sequences used in the study.
Genotype Protein Coding
nucleotide
change
Amino
Acid
Change
Allele (wild type)
Frequency
Primer Oligonucleotide sequence
A B
UGT1A6*2 UGT1A6.2 A541G Thr181Ala 0.673 0.673 – Caucasian
(American)
Forward
primer
GGAGAGCAAGTTTGATGCTCTT
0.821 – Mixed
population
Reverse
primer
CAGCTGATGCGAGTTCTTCA
UGT1A7*12 UGT1A7.12 T622C/
C760T
W208R/
R254X
0.606 0.420 – Caucasian
(American)
Forward
primer
GTGCCCTGCTCCTCTTTCCTAT
0.380 African
(American)
Reverse
primer
ACGGGTTTGGGATACTCCAAA
UGT1A8*3 UGT1A8.3 G830A C277Y 00 0.551 Caucasian
(American)
Forward
primer
GGTATCAACTACCATCAGG
0.760 Caucasian
(French Canadian)
Reverse
primer
CCCTGATGGTAGTTGATACC
UGT1A9*3 UGT1A9.3 T98C M33T 00 0.063 – Caucasian
(American)
Forward
primera
CCTGCTCTCAGCTGCAGTTCTCT
0.09 – African
(American)
Reverse
primer
CTTCACTGTGCAATTCAGTGATCTT
0 – Asian
UGT2B7*2 UGT2B7.2 C802T Y268H 0.508 0.460 – Caucasian
(American)
Forward
primer
GTAAATATCTGTGTCATC
0.730 – Asian
(Japanese)
Reverse
primer
GACTATAGAATCATTTCTACTG
UGT2B15*2 UGT1B15.2 G253T D85Y 0.662 0.448 – Caucasian
(American)
Forward
primer
GAGCTTGTTCAGAGGGGTCA
0.614 – African
(American)
Reverse
primer
CAAAACTGCATCTTTACAGAGCTT
0.630 – Hispanic
(American)
A = Saudi Population (Current Study); B = Other Populations.
a Also detect G8A mutation.
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sequencing using BigDye Terminator Cycle Sequencing V3.1
Kit and 3730xl DNA Analyzer (Applied Biosystems, Foster
City, CA, USA). DNA sequences were analyzed using the Seq-
man program of the DNASTAR analysis package (Lasergene,
Madison, WI, USA).
2.3. Statistical analysis
Frequencies of the studied polymorphisms are expressed as
percentage with 95% confidence interval (95% CI). Data were
analyzed using Microsoft Excel Program (Microsoft Inc.,
Seattle, WA, USA).
3. Results
Allele and genotype frequencies of UGT1A6*2, 1A7*12,
1A8*3, 1A9*3, 2B7*2, and 2B15*2 are given in Table 2. The
most common variant for UGT1A6*2 A/G genotype was the
homozygous repeat (AA) with a frequency of 46.5% and the
most common allele was (A) with a frequency of 67.3%. For
UGT1A6*2 A/C, the most common variant for this genotype
was the heterozygous repeat (AC) with a frequency of 45.3%
and the most common allele was (A) with a frequency of
65.2%. Similarly, the most common variant for UGT1A7*12Please cite this article in press as: Alkharfy, K.M. et al., Prevalence of UDP-glucurono
2B15*2) in a Saudi population. Saudi Pharmaceutical Journal (2016), http://dx.doi.oT/C genotype was the repeat (TC) with a frequency of
78.7%, while the most common allele was (C) with a frequency
of 60.6%. Both the homozygous (CC) and the heterozygous
repeats (CT) of UGT1A7*12 C/T had almost same frequency
with the homozygous (CC) repeat having a frequency of
50.3% while the heterozygous repeat (CT) had a frequency
of 49.7%. The most common allele was (C) with a frequency
of 75.1%. For UGT1A8*3 G/A and UGT1A9*3 T/C, both
these genotypes showed only homozygous pattern in all the
screened subjects.
For UGT2B7*2 (C802T), the most common variant was
the heterozygous repeat (TC) with a frequency of 57.3% and
both the alleles (C) and (T) showed a similar frequency of
50.8% and 49.2%, respectively. UGT2B15*2 (G253T) showed
the heterozygous repeat variant (TG) with a frequency of
62.3% and the most common allele found was (G) with a fre-
quency of 66.2%.
4. Discussion
There is substantial evidence now which implies that glu-
curonidation can be attributed to inter-individual and inter-
ethnic variations (Burchell et al., 2000). The UGT family of
genes is extremely diversified. This can be best illustrated by
the UGT1A1 gene, which contains over 50 genetic lesionssyltransferase polymorphisms (UGT1A6*2, 1A7*12, 1A8*3, 1A9*3, 2B7*2, and
rg/10.1016/j.jsps.2016.05.009
Table 2 Allele and genotype frequencies of the studied UGT polymorphisms in a Saudi population.
UGT1A6*2(R)A/G AA GG AG Total
N 86 19 77 185
N% (95% CI) 46.5 (39.3,53.7) 10.3 (5.9,14.6) 41.6 (34.5,48.7)
Allele A G
N 249 115 370
N% (95% CI) 67.3 (62.5,72.1) 31.1 (26.3,35.8)
UGT1A6*2(R)A/C AA CC GG AC Total
N 80 22 1 85 188
N% (95% CI) 42.5 (35.45,49.6) 11.7 (7.1,16.3) 0.5 (0.01,2.9) 45.3 (38.1,52.3)
Allele A C G
N 245 129 2 376
N% (95% CI) 65.2 (60.3,69.9) 34.3 (29.5,39.1) 0.5 (0.06,1.9)
UGT1A7*12(R)T/C CC TC Total
N 40 148 188
N% (95% CI) 21.3 (15.4,27.1) 78.7 (72.8,84.6)
Allele C T
N 228 148 376
N% (95% CI) 60.6 (55.7,65.6) 39.4 (34.4,44.3)
UGT1A7*12(R)C/T CC CT TT Total
N 94 93 00 187
N% (95% CI) 50.3 (43.1,57.4) 49.7 (42.5,56.9) 00
Allele C T
N 281 93 374
N% (95% CI) 75.1 (70.7,79.5) 24.9 (20.5,29.2)
UGT1A8*3(F)G/A GG GA AA Total
N 190 00 00
N% (95% CI) 100 00 00
Allele G A
N 380 00 00
N% (95% CI) 100 00 00
UGT1A9*3(R)T/C TT TC CC
N 188 00 00
N% (95% CI) 100 00 00
Allele T
N 376
N% (95% CI) 100
UGT2B7*2(C802T) CC TC TT Total
N 41 106 38 185
N% (95% CI) 22.2 (16.1,28.1) 57.3 (50.1,64.4) 20.5 (14.7,26.4) 100
Allele C T
N 188 182 370
N% (95% CI) 50.8 (45.7,55.9) 49.2 (44.1,54.3) 100
UGT2B15*2(G253T) GG TG TT Total
N 67 119 5 191
N% (95% CI) 35.1 (28.3,41.8) 62.3 (55.4,69.2) 2.6 (0.35,4.8) 100
Allele G T
N 253 129
N% (95% CI) 66.2 (61.5,70.9) 33.8 (29.0,38.3) 100
4 K.M. Alkharfy et al.(Kadakol et al., 2000), most of which impact its functional
properties as well as its expression.
UGT1A6*2 mutation influences aspirin metabolism, while
UGT1A7*12 may be used to predict mycophenolic acid
(MPA) clearance. UGT1A6*2 codes for an enzyme compressPlease cite this article in press as: Alkharfy, K.M. et al., Prevalence of UDP-glucurono
2B15*2) in a Saudi population. Saudi Pharmaceutical Journal (2016), http://dx.doi.its catalytic activity against many UGT1A6 substrates.
UGT1A6 also plays a significant role in the metabolism of
aspirin and other non-steroidal anti-inflammatory agents
(NSAIDs). UGT1A6*2 has also been shown to influence the
protective effect of aspirin (Bigler et al., 2001). It has beensyltransferase polymorphisms (UGT1A6*2, 1A7*12, 1A8*3, 1A9*3, 2B7*2, and
org/10.1016/j.jsps.2016.05.009
Prevalence of UDP-glucuronosyltransferase polymorphisms 5found that 87% of individuals, who are homozygous for the
UGT1A1*28 allele, which is present in individuals with Gil-
berts syndrome, are also homozygous for the UGT1A6*2
allele (Wilbert-HM et al., 2003). This suggests that due to
the presence of both UGT1A1*28 and UGT1A6*2 genotypes,
such individuals may have a reduced capability to glu-
curonidate bilirubin.
The UGT1A7 allelic polymorphism may change individual
vulnerability to cancer by decreasing the capacity to detoxify.
It has been shown that UGT1A7*12 causes a 70% decline in
the transcriptional performance (Iyer et al., 1998). There have
been many SNP association studies which have demonstrated
that there is an association of homozygous UGT1A7*12 in
75% individuals with homozygous UGT1A1*28 (Wilbert-
HM et al., 2003).
Our data indicate a considerable number of Saudis harbor
both these polymorphisms, UGT1A6*2 and UGT1A7*12,
which suggest they may be at a risk of developing Gilbert’s
syndrome. It has also been shown that the amalgam of differ-
ent variations of UGT1A1 and UGT1A7 can be used to antic-
ipate irinotecan toxicity (Lankisch et al., 2008). Allelic
differences in any of the UGT loci can give rise to important
biological modifications in drug metabolism ability and in
some enzymes that are recognized as glucuronidate carcino-
gens, an absence of action may play a significant role in the eti-
ology of a carcinogenic incident.
The UGT1A8 is a very rare form of polymorphism and is
expressed entirely in the extra-hepatic tissues of the gastroin-
testinal tract (Tukey and Strassburg, 2000, 2001). It has been
found that UGT1A8 plays a role in the metabolism of dietary
and environmental carcinogens (Mojarrabi and Mackenzie,
1998; Nowell et al., 1999; Cheng et al., 1998, 1999).
UGT1A8*3 has been classified as a low-activity protein on
various substrates, including a reduction in MPAG (MPA glu-
curonide metabolite) formation (Huang et al., 2002). This indi-
cates that it is integral for enzyme function and substrate
binding. However, studies have shown that UGTlA8*3 is very
rare in humans, which can be considered as an useful marker
in evaluating for colorectal cancer. Since our data indicate that
Saudis do not harbor any allelic variation for this genotype, it
concurs with other studies which report this as a very rare form
of polymorphism in other populations around the world as well.
UGT1A9*3 causes decreased glucuronidation of mycophe-
nolic acid (Bernard et al., 2004), 4-hydroxyestrone, 4-
hydroxyestradiol (Thibaudeau et al., 2006) and reduced activ-
ity of propofol glucuronidation (Girard et al., 2004). Studies
have shown the genetic variant in codon 33 of UGT1A9
may help in predicting the individual’s vulnerability to the tox-
icity of drugs, their clearance rate and side effects. Genetic
polymorphisms of UGT1A9 gene are very rare among popula-
tions (Villeneuve et al., 2003). Our data demonstrate the lack
of polymorphism for this genotype in Saudi population as
well. Hence, UGT1A9*3 is likely to be a clinically insignificant
polymorphism in Saudis. However, additional analysis of
functional properties of this polymorphism may help to deter-
mine the metabolizer phenotype in populations, which may
help in optimizing the drug dose and development of personal-
ized medicine in the future.
UGT2B7 is involved in the glucuronidation of catechol
estrogens, bile acids, morphine, MPA, oxazepam and zidovu-
dine with overlapping substrate specificities (Mackenzie
et al., 2003). Additionally, UGT2B7*2 allele is affiliated withPlease cite this article in press as: Alkharfy, K.M. et al., Prevalence of UDP-glucurono
2B15*2) in a Saudi population. Saudi Pharmaceutical Journal (2016), http://dx.doi.odefective morphine glucuronidation in vitro and hence,
homozygous infants with the UGT2B7*2 allele, may be at an
enhanced risk of potential life-threatening CNS depression
after codeine treatment (Coffman et al., 1997; Ishii et al.,
1997). In fact, UGT2B7 exclusively catalyzes the glucuronida-
tion of codeine, morphine and zidovudine (AZT) (Barbier
et al., 2000) and non-drug xenobiotic substrates including
hydroxylated derivatives of the prototypic carcinogens 2-
acetylaminofluorene and benzo[a]-pyrene. Despite being pri-
marily involved in the detoxification of xenobiotic and endoge-
nous substrates, UGT2B7 also plays a vital role in forming
bioactive or even toxic compounds like the highly cholestatic
D-ring glucuronides of estrogens and the acyl-glucuronides of
drugs such as diflunisal that binds to proteins and triggers toxic
immunological responses (Worrall and Dickinson, 1995). Vari-
ous studies have demonstrated that UGT2B7*2 polymorphism
nominally impacts enzyme activity and substrate specificity of
UGT2B7 (Coffman et al., 1998; Holthe et al., 2002a,b;
Bhasker et al., 2000). However, a wide inter-individual variance
in the ability to glucuronidate morphine (McQuay et al., 1990;
Klepstad et al., 2000; Faura et al., 1998) and AZT (Mentre
et al., 1993) suggests that this or other polymorphisms in
UGT2B7 may contribute to morphine metabolism variability.
UGT2B15*2 glucuronidates many drugs such as oxazepam,
lorazepam and rofecoxib. Our data indicate that heterozygous
repeat of UGT2B15*2 accounts for about 62% of the study
population. Studies have shown that prostate cancer patients
are significantly more likely to be homozygous for the lower
activity UGT2B15*2 allele than control individuals (Holthe
et al., 2000a,b) Homozygous repeat alleles represent increased
risk of prostate cancer associated with this low activity variant.
Therefore, our data indicate that Saudis are at a low risk of
being afflicted with prostate cancer.
5. Conclusion
This study indicates that Saudi population harbors some
important UGT mutations which can affect enzyme activity.
Several functional polymorphisms in UGT 1A and 2B subfam-
ilies are associated with altered glucuronidation activity of
important endogenous compounds and clinically used drugs.
These variations may assist in changing the pharmacokinetic
profile of a drug as well as to the etiology of a possible toxic
reaction. The current findings also support the need to evalu-
ate UGT polymorphism frequencies within the populations
of specific diseases and within patient clinical covariates to
understand the contribution in disease pathogenesis and
response to drug therapy.
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